SAB Biotherapeutics vs Scinai Immunotherapeutics
SABS and SCNI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SABS and SCNI compare
SAB Biotherapeutics scores higher on the StockData Score (8 against 6 for Scinai Immunotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SABS | SCNI |
|---|---|---|
| Size and price | ||
| Market cap | $269M | – |
| Share price | $2.96 | $0.400 |
| Change, 1 year | −13.2% | −96.3% |
| Change, 5 years | −97.3% | −100.0% |
| Beta (5Y) | 1.38 | 1.48 |
| Employees | 86 | 45 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 1.3× | – |
| Growth | ||
| Revenue growth (TTM) | – | 99.2% |
| Net income growth (TTM) | −530% | −273% (better) |
| Profitability | ||
| Gross margin | – | −202% |
| Operating margin | – | −575% |
| Net margin | – | −634% |
| FCF margin | – | −462% |
| Return on equity | −42.8% (better) | −84.8% |
| Return on invested capital | −83.4% | −74.7% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 7.28 (better) | 1.56 |
| Altman Z-score | 4.78 | – |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 75.2% | – |
| Held by insiders | 30.2% | 7.4% |
| Short interest, % of float | 7.9% | – |
Go deeper
- SABS stock overview
- SABS income statement
- SABS valuation and score
- SCNI stock overview
- SCNI income statement
- SCNI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.